TPMT Genotyping to Predict Myelosuppression Risk
Author Information
Author(s): Nguyen Christine M., Mendes Margaret A., Ma Joseph D.
Primary Institution: VA San Diego Healthcare System and UCSD Skaggs School of Pharmacy and Pharmaceutical Sciences
Hypothesis
Can TPMT genotyping predict the risk of myelosuppression in patients treated with thiopurine drugs?
Conclusion
TPMT genotyping may help predict myelosuppression risk, but it should not replace regular blood monitoring.
Supporting Evidence
- Approximately 86-97% of patients have the wild-type TPMT genotype.
- Patients with the homozygous TPMT variant genotype have the highest risk of severe myelosuppression.
- TPMT genotyping may help guide dose adjustments for thiopurine drugs.
Takeaway
Doctors can test a gene to see if a medicine might make patients sick, but they still need to check their blood regularly.
Methodology
The TPMT genotype assay uses PCR amplification followed by single nucleotide primer extension to detect specific TPMT alleles.
Limitations
The TPMT genotype test cannot detect all mutations and should not be the only method used to assess myelosuppression risk.
Participant Demographics
The study included patients of various ethnicities, including Caucasians, Asians, and African Americans.
Statistical Information
Confidence Interval
95% CI = 4.12-83.60 for homozygous TPMT genotype developing severe myelosuppression.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website